This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Incyte (INCY) Label Expansion for Ruxolitinib Cream Delayed
by Zacks Equity Research
Incyte' s (INCY) sNDA seeking label expansion of ruxolitinib cream gets extended by three months by the FDA for reviewing additional information.
AnaptysBio's (ANAB) Acne Study on Imsidolimab Fails to Meet Goal
by Zacks Equity Research
AnaptysBio's (ANAB) phase II study evaluating imsidolimab for treating moderate-to-severe acne, fails to show improvement over placebo in top-line primary or secondary endpoints. Shares down.
AstraZeneca's (AZN) Fasenra sBLA for Nasal Polyps Gets CRL
by Zacks Equity Research
The FDA gives CRL to AstraZeneca's (AZN) sBLA for Fasenra for chronic rhinosinusitis with nasal polyps (CRSwNP) for want of additional clinical
Moderna (MRNA) Early-Stage HIV Vaccine Study Begins, Stock Up
by Zacks Equity Research
Moderna (MRNA) starts dosing in an mRNA-based HIV vaccine study.
AstraZeneca (AZN) Stock Up 27% in a Year: What Lies Ahead?
by Zacks Equity Research
AstraZeneca's (AZN) stock has risen 26.9% in the past year compared with an increase of 22.3% for the industry.
Should You Invest in the VanEck Biotech ETF (BBH)?
by Zacks Equity Research
Sector ETF report for BBH
Sanofi's (SNY) Breast Cancer Candidate Misses Goal in Study
by Zacks Equity Research
Sanofi's (SNY) phase II AMEERA-3 study, investigating amcenestrant in ER+/HER2- advanced/metastatic breast cancer, fails to meet the primary endpoint.
Immunome (IMNM) COVID-19 Cocktail Hold Lifted, Shares Gain
by Zacks Equity Research
Immunome (IMNM) gains as FDA lifts clinical hold on its Investigational New Drug (IND) application for its antibody cocktail (IMM-BCP-01) for the treatment of COVID-19.
Novartis (NVS) Announces Data on Zolgensma, Acquires Coalesce
by Zacks Equity Research
Novartis (NVS) reports positive data on SMA treatment from a phase III study. It also acquires Coalesce Product Development Limited to strengthen its respiratory and complex generics business.
AbbVie (ABBV) Inks Deal for Neuropsychiatric Conditions
by Zacks Equity Research
AbbVie (ABBV) forges an alliance with Gedeon Richter to develop novel treatments for neuropsychiatric diseases. Both collaborated in the past too on the blockbuster schizophrenia drug Vraylar.
Emergent (EBS) Begins Dosing in Phase I Cyanide Poisoning Study
by Zacks Equity Research
Emergent (EBS) initiates dosing in a phase I study evaluating stabilized isoamyl nitrite, the company's investigational single-use intranasal spray for treating acute cyanide poisoning.
Why is Viatris (VTRS) Stock Down 25% in the Year So Far?
by Zacks Equity Research
Viatris (VTRS) stock drops 25% in the year so far as investors do not seem to be impressed by the impending sale of its biosimilar business.
Moderna (MRNA) Starts Omicron-Specific Bivalent Booster Study
by Zacks Equity Research
Moderna (MRNA) administers the first dose in the phase II study of its Omicron-specific bivalent booster candidate (mRNA-1273.214). It expects to enrol 375 subjects for the same in the United States.
Denali (DNLI) Begins Frontotemporal Dementia-Granulin Study
by Zacks Equity Research
Denali (DNLI) starts an early-stage study of DNL593 for treating frontotemporal dementia (FTD) due to mutations in the granulin gene (GRN) in collaboration with Takeda.
Acadia (ACAD) Stock Up on FDA's Action Date for Nuplazid sNDA
by Zacks Equity Research
Acadia (ACAD) gets an action date of Aug 4, 2022, from the FDA for its resubmitted sNDA for pimavanserin to treat hallucinations and delusions associated with Alzheimer's disease psychosis.
Catalyst (CPRX) Skyrockets 110% Over a Year: Here's Why
by Zacks Equity Research
Catalyst's (CPRX) stock price has more than doubled in the past year, driven by its sole marketed drug, Firdapse, approved for the treatment of Lambert-Eaton Myasthenic Syndrome in adults.
Pfizer (PFE) Begins Pediatric Study on COVID Pill Paxlovid
by Zacks Equity Research
Pfizer's (PFE) Paxlovid is the first oral antiviral pill to be studied in a pediatric clinical study.
Intellia's (NTLA) NTLA-5001 Gets FDA Orphan Drug Tag for AML
by Zacks Equity Research
Intellia's (NTLA) investigational gene-editing therapy, NTLA-5001, gets an Orphan Drug tag from the FDA for AML.
Voyager (VYGR) Gains on Deal With Novartis for Gene Therapies
by Zacks Equity Research
Voyager (VYGR) stock rises on the license option agreement with Novartis to get a target-specific access to next-generation TRACER AAV capsids for gene therapy programs.
BioNTech (BNTX), Regeneron Expand Agreement for Lung Cancer Study
by Zacks Equity Research
BioNTech (BNTX) expands its strategic collaboration deal with Regeneron to evaluate the combo of BNT116 plus Libtayo for treating advanced non-small cell lung cancer.
Gilead's (GILD) Trodelvy Late-Line Breast Cancer Study Meets Goal
by Zacks Equity Research
While Gilead's (GILD) phase III study evaluating Trodelvy in late-line HR+/HER- breast cancer did achieve its primary endpoint, the lack of numerical data puts ambiguity on the significance of results.
Horizon's (HZNP) sBLA for Krystexxa Gets FDA Priority Review
by Zacks Equity Research
The FDA grants priority review to Horizon's (HZNP) sBLA for Krystexxa plus methotrexate to treat people living with uncontrolled gout. A decision is due on Jul 7, 2022.
AbbVie (ABBV) Outperforms Industry This Year So Far: What Next?
by Zacks Equity Research
AbbVie (ABBV) has several new drugs with the potential to drive revenues once Humira loses U.S. exclusivity in 2023. Its early and mid-stage pipeline has several candidates with blockbuster potential.
bluebird (BLUE) Posts Q4 Loss, Hit by Regulatory Pipeline Woes
by Zacks Equity Research
bluebird (BLUE) reports in-line fourth-quarter 2021 earnings but misses on revenues. The FDA placing clinical holds on BLUE's pipeline candidates does not augur well for the stock.
FDA Nods to Bristol Myers' (BMY) Opdivo for Additional Indication
by Zacks Equity Research
Bristol Myers' (BMY) immuno-oncology Opdivo gets FDA nod for adult patients with resectable non-small cell lung cancer in the neoadjuvant setting in combination with platinum-doublet chemotherapy.